AAAAAA

   
Results: 1-22 |
Results: 22
TARGETED THERAPY IN OVARIAN, FALLOPIAN-TUBE, AND PERITONEAL CANCER - A PHASE-I STUDY OF VACCINATION WITH THE LEWIS Y-KLH CONJUGATE AND QS-21
Authors: SABBATINI P LIVINGSTON P LOYD K AGHAJANIAN C SPRIGGS D POYNOR E CHI D BROWN C BARAKAT R DANISHEFSKY S HOSKINS W VENKATRAMAN ES GOODRICH K CURTIN J
Citation: P. Sabbatini et al., TARGETED THERAPY IN OVARIAN, FALLOPIAN-TUBE, AND PERITONEAL CANCER - A PHASE-I STUDY OF VACCINATION WITH THE LEWIS Y-KLH CONJUGATE AND QS-21, Annals of oncology, 9, 1998, pp. 317-317
PHASE-II STUDY OF DOSE-DENSE HIGH-DOSE CHEMOTHERAPY TREATMENT WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT AS PRIMARY-TREATMENT FOR PATIENTS WITH ADVANCED OVARIAN-CANCER
Authors: AGHAJANIAN C FENNELLY D SHAPIRO F WALTZMAN R ALMADRONES L OFLAHERTY C OCONNER K VENKATRAMAN E BARAKAT R CURTIN J BROWN C REICH L WUEST D NORTON L HOSKINS W SPRIGGS DR
Citation: C. Aghajanian et al., PHASE-II STUDY OF DOSE-DENSE HIGH-DOSE CHEMOTHERAPY TREATMENT WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT AS PRIMARY-TREATMENT FOR PATIENTS WITH ADVANCED OVARIAN-CANCER, Journal of clinical oncology, 16(5), 1998, pp. 1852-1860
A PRELIMINARY EVALUATION OF NELFINAVIR MESYLATE, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE, TO TREAT HIV-INFECTION
Authors: MARKOWITZ M CONANT M HURLEY A SCHLUGER R DURAN M PETERKIN J CHAPMAN S PATICK A HENDRICKS A YUEN GJ HOSKINS W CLENDENINN N HO DD
Citation: M. Markowitz et al., A PRELIMINARY EVALUATION OF NELFINAVIR MESYLATE, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE, TO TREAT HIV-INFECTION, The Journal of infectious diseases, 177(6), 1998, pp. 1533-1540
THE USE OF PHOSPHOR PLATES FOR QUANTITATIVE-ANALYSIS OF RADIOLABELED MONOCLONAL-ANTIBODY LOCALIZATION
Authors: HUMM JL FEDERICI M FINSTAD CL LLOYD K LARSON S HOSKINS W DIVGI C
Citation: Jl. Humm et al., THE USE OF PHOSPHOR PLATES FOR QUANTITATIVE-ANALYSIS OF RADIOLABELED MONOCLONAL-ANTIBODY LOCALIZATION, The Journal of nuclear medicine, 38(5), 1997, pp. 976-976
FOLLOW-UP OF MEMORIAL-SLOAN-KETTERING-CANCER-CENTER PATIENTS TREATED ON NATIONAL-CANCER-INSTITUTE TREATMENT REFERRAL CENTER PROTOCOL-9103 -PACLITAXEL IN REFRACTORY OVARIAN-CANCER
Authors: MARKMAN M HAKES T BARAKAT R CURTIN J ALMADRONES L HOSKINS W
Citation: M. Markman et al., FOLLOW-UP OF MEMORIAL-SLOAN-KETTERING-CANCER-CENTER PATIENTS TREATED ON NATIONAL-CANCER-INSTITUTE TREATMENT REFERRAL CENTER PROTOCOL-9103 -PACLITAXEL IN REFRACTORY OVARIAN-CANCER, Journal of clinical oncology, 14(3), 1996, pp. 796-799
PHASE-I STUDY OF TAXOL ADMINISTERED WEEKLY IN PATIENTS WITH PERSISTENT OVARIAN-CANCER
Authors: FENNELLY D SHAPIRO F SPRIGGS D AGHAJANIAN C FRANCIS P LEWIS JL JONES W CURTIN J BARAKAT R HOSKINS W
Citation: D. Fennelly et al., PHASE-I STUDY OF TAXOL ADMINISTERED WEEKLY IN PATIENTS WITH PERSISTENT OVARIAN-CANCER, European journal of cancer, 31A, 1995, pp. 923-923
DOSE-ESCALATION OF PACLITAXEL WITH HIGH-DOSE CYCLOPHOSPHAMIDE, WITH ANALYSIS OF PROGENITOR-CELL MOBILIZATION AND HEMATOLOGIC SUPPORT OF ADVANCED OVARIAN-CANCER PATIENTS RECEIVING RAPIDLY SEQUENCED HIGH-DOSE CARBOPLATIN CYCLOPHOSPHAMIDE COURSES
Authors: FENNELLY D SCHNEIDER J SPRIGGS D BENGALA C HAKES T REICH L BARAKAT R CURTIN J MOORE MAS HOSKINS W NORTON L CROWN J
Citation: D. Fennelly et al., DOSE-ESCALATION OF PACLITAXEL WITH HIGH-DOSE CYCLOPHOSPHAMIDE, WITH ANALYSIS OF PROGENITOR-CELL MOBILIZATION AND HEMATOLOGIC SUPPORT OF ADVANCED OVARIAN-CANCER PATIENTS RECEIVING RAPIDLY SEQUENCED HIGH-DOSE CARBOPLATIN CYCLOPHOSPHAMIDE COURSES, Journal of clinical oncology, 13(5), 1995, pp. 1160-1166
PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY
Authors: FRANCIS P ROWINSKY E SCHNEIDER J HAKES T HOSKINS W MARKMAN M
Citation: P. Francis et al., PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY, Journal of clinical oncology, 13(12), 1995, pp. 2961-2967
INTRAPERITONEAL PACLITAXEL - A POSSIBLE ROLE IN THE MANAGEMENT OF OVARIAN-CANCER
Authors: MARKMAN M FRANCIS P ROWINSKY E HOSKINS W
Citation: M. Markman et al., INTRAPERITONEAL PACLITAXEL - A POSSIBLE ROLE IN THE MANAGEMENT OF OVARIAN-CANCER, Seminars in oncology, 22(3), 1995, pp. 84-87
RATIONALE FOR THE INTRAPERITONEAL ADMINISTRATION OF PACLITAXEL (TAXOL(R)) IN THE TREATMENT OF OVARIAN-CANCER
Authors: MARKMAN M FRANCIS P ROWINSKY E HAKES T REICHMAN B JONES W LEWIS JL RUBIN S CURTIN J BARAKAT R PHILLIPS M HOSKINS W
Citation: M. Markman et al., RATIONALE FOR THE INTRAPERITONEAL ADMINISTRATION OF PACLITAXEL (TAXOL(R)) IN THE TREATMENT OF OVARIAN-CANCER, International journal of gynecological cancer, 4, 1994, pp. 19-22
SYMPTOM PREVALENCE, CHARACTERISTICS AND DISTRESS IN A CANCER POPULATION
Authors: PORTENOY RK THALER HT KORNBLITH AB LEPORE JM FRIEDLANDERKLAR H COYLE N SMARTCURLEY T KEMENY N NORTON L HOSKINS W SCHER H
Citation: Rk. Portenoy et al., SYMPTOM PREVALENCE, CHARACTERISTICS AND DISTRESS IN A CANCER POPULATION, Quality of life research, 3(3), 1994, pp. 183-189
HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT
Authors: FENNELLY D VAHDAT L SCHNEIDER J REICH L HAMILTON N HAKES T RAPTIS G WASSERHEIT C KRITZ A GULATI S MARKMAN M HOSKINS W NORTON L CROWN J
Citation: D. Fennelly et al., HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT, Seminars in oncology, 21(2), 1994, pp. 21-25
NATIONAL SURVEY OF OVARIAN-CARCINOMA .4. PATTERNS OF CARE AND RELATEDSURVIVAL FOR OLDER PATIENTS
Authors: HIGHTOWER RD NGUYEN HN AVERETTE HE HOSKINS W HARRISON T STEREN A
Citation: Rd. Hightower et al., NATIONAL SURVEY OF OVARIAN-CARCINOMA .4. PATTERNS OF CARE AND RELATEDSURVIVAL FOR OLDER PATIENTS, Cancer, 73(2), 1994, pp. 377-383
A COMPARATIVE-STUDY OF INTACT AND F(AB')2 FRAGMENTS OF MONOCLONAL-ANTIBODY MX-35 IN A XENOGRAFT MODEL
Authors: KOSTAKOGLU L RUBIN SC FEDERICI M FINSTAD CL LARSON SM HOSKINS W LLOYD KO
Citation: L. Kostakoglu et al., A COMPARATIVE-STUDY OF INTACT AND F(AB')2 FRAGMENTS OF MONOCLONAL-ANTIBODY MX-35 IN A XENOGRAFT MODEL, The Journal of nuclear medicine, 34(5), 1993, pp. 216-216
MITOMYCIN-C PLUS A 3-DAY CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL - AN INACTIVE SALVAGE REGIMEN FOR PLATINUM-RESISTANT OVARIAN-CARCINOMA
Authors: REICHMAN B MARKMAN M HAKES T RUBIN S JONES W CURTIN J BARAKAT R ALMADRONES L LEWIS JL HOSKINS W
Citation: B. Reichman et al., MITOMYCIN-C PLUS A 3-DAY CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL - AN INACTIVE SALVAGE REGIMEN FOR PLATINUM-RESISTANT OVARIAN-CARCINOMA, Gynecologic oncology, 50(1), 1993, pp. 30-33
EVIDENCE SUPPORTING THE SUPERIORITY OF INTRAPERITONEAL CISPLATIN COMPARED TO INTRAPERITONEAL CARBOPLATIN FOR SALVAGE THERAPY OF SMALL-VOLUME RESIDUAL OVARIAN-CANCER
Authors: MARKMAN M REICHMAN B HAKES T RUBIN S LEWIS JL JONES W BARAKAT R CURTIN J ALMADRONES L HOSKINS W
Citation: M. Markman et al., EVIDENCE SUPPORTING THE SUPERIORITY OF INTRAPERITONEAL CISPLATIN COMPARED TO INTRAPERITONEAL CARBOPLATIN FOR SALVAGE THERAPY OF SMALL-VOLUME RESIDUAL OVARIAN-CANCER, Gynecologic oncology, 50(1), 1993, pp. 100-104
THE USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN TO PREVENT CARBOPLATIN-INDUCED ANEMIA
Authors: MARKMAN M REICHMAN B HAKES T RUBIN S JONES W LEWIS JL BARAKAT R CURTIN J ALMADRONES L HOSKINS W
Citation: M. Markman et al., THE USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN TO PREVENT CARBOPLATIN-INDUCED ANEMIA, Gynecologic oncology, 49(2), 1993, pp. 172-176
SALVAGE INTRAPERITONEAL MITOXANTRONE THERAPY OF OVARIAN-CANCER - INFLUENCE OF INCREASING THE VOLUME OF TREATMENT
Authors: MARKMAN M HAKES T REICHMAN B RUBIN S CURTIN J BARAKAT R JONES W LEWIS JL ALMADRONES L HOSKINS W
Citation: M. Markman et al., SALVAGE INTRAPERITONEAL MITOXANTRONE THERAPY OF OVARIAN-CANCER - INFLUENCE OF INCREASING THE VOLUME OF TREATMENT, Gynecologic oncology, 49(2), 1993, pp. 185-189
IMPACT OF AGE ON SURVIVAL OF PATIENTS WITH OVARIAN-CANCER
Authors: MARKMAN M LEWIS JL SAIGO P HAKES T RUBIN S JONES W REICHMAN B CURTIN J BARAKAT R ALMADRONES L MORRISSEY T HOSKINS W
Citation: M. Markman et al., IMPACT OF AGE ON SURVIVAL OF PATIENTS WITH OVARIAN-CANCER, Gynecologic oncology, 49(2), 1993, pp. 236-239
NATIONAL SURVEY OF OVARIAN-CARCINOMA .5. THE IMPACT OF PHYSICIANS SPECIALTY ON PATIENTS SURVIVAL
Authors: NGUYEN HN AVERETTE HE HOSKINS W PENALVER M SEVIN BU STEREN A
Citation: Hn. Nguyen et al., NATIONAL SURVEY OF OVARIAN-CARCINOMA .5. THE IMPACT OF PHYSICIANS SPECIALTY ON PATIENTS SURVIVAL, Cancer, 72(12), 1993, pp. 3663-3670
NATIONAL SURVEY OF OVARIAN CARCINOMA-VI - CRITICAL-ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING SYSTEM
Authors: NGUYEN HN AVERETTE HE HOSKINS W SEVIN BU PENALVER M STEREN A
Citation: Hn. Nguyen et al., NATIONAL SURVEY OF OVARIAN CARCINOMA-VI - CRITICAL-ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING SYSTEM, Cancer, 72(10), 1993, pp. 3007-3011
RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN-CANCER - A CRITICAL NEEDFOR PRECISE DEFINITIONS OF THE TREATED POPULATION
Authors: MARKMAN M HOSKINS W
Citation: M. Markman et W. Hoskins, RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN-CANCER - A CRITICAL NEEDFOR PRECISE DEFINITIONS OF THE TREATED POPULATION, Journal of clinical oncology, 10(4), 1992, pp. 513-514
Risultati: 1-22 |